失调
医学
肝硬化
微生物群
肝病
肠道菌群
肠道微生物群
脂肪性肝炎
疾病
失代偿
非酒精性脂肪肝
免疫学
胃肠病学
脂肪肝
内科学
生物信息学
生物
作者
Chathur Acharya,Jasmohan S. Bajaj
标识
DOI:10.1016/j.gtc.2016.09.013
摘要
Chronic liver disease, cirrhosis, and its complications are epidemic worldwide. Most complications are mediated through a dysfunctional gut-liver axis. New techniques have made culture-independent analysis of the gut microbiome widespread. With insight into an unfavorable microbiome (dysbiosis) and how it affects liver disease, investigators have discovered new targets to potentially improve outcomes. Dysbiosis is associated with endotoxemia and propagates liver injury due to nonalcoholic steatohepatitis and alcohol. The composition and functionality of the microbiome changes with the development of cirrhosis, decompensation, and with treatments for these conditions. Gut microbiota can be used to predict clinically relevant outcomes in cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI